The Safety and Effectiveness of the Extended Longevity Protocol on the Epigenetic Aging Rate in Healthy Individuals
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Epigenetic Age
研究概览
简要总结
The purpose of this study is to quantifiably determine if the Extended Longevity Protocol has a significant clinical effect on epigenetic age.
详细描述
This is a prospective non-randomized clinical study of 15 patients to determine if the safety and effectiveness of the Extended Longevity Protocol's impact on the nine determinant factors of aging can decelerate aging.
There is evidence that the Extended Longevity Protocol decelerates aging and the risk of age-related diseases. The aim of this pilot study is to evaluate the safety, efficacy and feasibility of the Extended Longevity Protocol as an effective treatment option to improve clinical care of healthy individual's biological age thus prolonging longevity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 55 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •8 Men and 7 Women
- •Must between 55-75 years old
- •Patient must be able to comply with treatment plan and laboratory tests
- •Patients must have adequate immune system function, with no known immunodeficiency disease
排除标准
- •Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
- •No immune system issues or immunodeficiency disease
- •No history of viral illness which could be reactivated by immune downregulation
- •Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) disease
- •Diagnosis of a transient ischemic attack in the 6 months prior to screening
- •Patients infected with hepatitis, C or HIV
- •Patients with Body Mass Index (BMI) > 40 kg/m2
- •Presence of active infection
- •Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study
- •Unable or unwilling to provide required blood sample for testing
结局指标
主要结局
Epigenetic Age
时间窗: Testing will compare the change in results after completion of intervention with baseline
serum epigenetic aging test
次要结局
未报告次要终点